The City’s Latest Forecasts For AstraZeneca Plc

How might earnings at AstraZeneca plc (LON: AZN) change in the years to come?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s always worth keeping an eye on the earnings forecasts for your favourite companies, especially if you use forward price-to-earnings (P/E) ratios to gauge when to buy and sell your shares.

If City brokers have been revising their projections of late, your investments may not be as cheap — or expensive — as you think!

Today I’m looking at the earnings per share (EPS) forecasts for AstraZeneca (LSE: AZN) (NYSE: AZN.US), the global pharmaceutical company. All figures for the company are courtesy of S&P Capital IQ.

A bargain?

The consensus for 2013 is for a normalised EPS of 333p (519 US cents), which puts the 3,183p shares on a forward P/E of 9.6. To put that into some perspective, at its current level of 6,510 the FTSE 100 is trading on a P/E of around 16.

So, if you believe the company will start to deliver better earnings over the next few years, a P/E of 9.6 might suggest that AstraZeneca is a bargain that the market is missing.

Or declining prospects?

However, City analyst estimates suggest that earnings may fall to 318p (495 US cents) per share in 2014, falling further to 312p (486 US cents) for 2015, and sinking to just 274p (427 US cents) in 2017.

Such forecasts imply that the current P/E of almost 10 reflects the anticipated decline in earnings, rather than any fundamental underpricing of the company.

The data from S&P Capital IQ also indicate total revenue at AstraZeneca will fall from 2012’s $28bn to only $22bn by 2017 and that EBITDA will decline sharply to just $7.6bn in 2017, which would be a drop of nearly 40% from last year’s £12.3bn.

All told, the forecasts seem pessimistic, with earnings set to fall significantly over the next few years, with that pessimism reflected by that 9.6 near-term P/E ratio.

What next?

Whether these projections make AstraZeneca a buy, a hold or a sell is, of course, up to you.

But if you’re looking for some high-quality investment opportunities, you should definitely read the Motley Fool’s special report , “5 Shares To Retire On“.

This exclusive report features five top-quality shares — companies that have an outstanding record of providing reliable shareholder returns — selected by our team of top share-pickers here at the Motley Fool.

Get your FREE copy now.

> Jon does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »